Mitochondrial impact of human immunodeficiency virus and antiretrovirals on infected pediatric patients with or without lipodystrophy

Pediatric Infectious Disease Journal

Volumn 30, Issue 11, 2011, Pages 992-995

  Morén, Constanza ^a,b   Noguera Julian, Antoni ^a   Rovira, Núria ^a   Corrales, Ester ^a   Garrabou, Glòria ^a,b   Hernández, Sandra ^a,b   Nicolás, Mireia ^a,b   Tobías, Ester ^a,b   Cardellach, Francesc ^a,b   Miró, Òscar ^a,b   Fortuny, Clàudia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

antiretrovirals; children; HIV; lipodystrophy; mitochondrial toxicity

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; BODY FAT DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRION; PRIORITY JOURNAL;

EID: 80054991792     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182253c54     Document Type: Article

References (21)

1. Côté H, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346:811-820. (Pubitemid 34984654)
2. Pilon AA, Lum JJ, Sanchez-Dardon J, et al. Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2002;46:2687-2691. (Pubitemid 34793489)
3. Casademont J, Barrientos A, Grau JM, et al. The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction. Brain. 1996;119:1357-1364. (Pubitemid 26300735)
4. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. New Engl J Med. 1990;322:1098-1105. (Pubitemid 20149526)
5. Viganò A, Giacomet V. Nucleoside analogues toxicities relate to mitochondrial dysfunction: focus on HIV-infected children. Antivir Ther. 2005; 10(suppl 2).
6. Caron-Debarle M, Lagathu C, Boccara C, et al. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med. 2010;16:218-229.
7. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factor for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;32:48-56. (Pubitemid 36091484)
8. Brinkman K, Smeitink JA, Romijn JA, et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999; 354:1112-1115. (Pubitemid 29452832)
9. Kim R, Rustein RM. Impact on antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients. Paediatr Drugs. 2010;12:187-199.
10. Saitoh A, Fenton T, Alvero C, et al. Impact of nucleoside reverse transcriptase inhibitors on mitochondrial in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother. 2007;51:4236-4242. (Pubitemid 350209871)
11. Rosso R, Nasi M, Di Biagio A, et al. Effects of the change from stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function. Pediatr Infect Dis J. 2008;27:17-21.
12. Cossarizza A, Pinti M, Moretti L, et al. Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antirretroviral therapy-related lipodystrophy. J Infect Dis. 2002;185:299-305. (Pubitemid 34107242)
13. Bradford M. A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
14. Miró Ò, López S, Rodríguez de la Concepción M, et al. Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine. J Acquir Immune Defic Syndr. 2004;37:1550-1555. (Pubitemid 39658190)
15. Nolan D, Hammond E, Martin A, et al. NRTI therapy is associated with mitochondrial DNA depletion, increased mitochondrial biogenesis and subcutaneous fat wasting in HIV infected patients (abstract 522). In: Final Program and abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment; Buenos Aires, Argentina; 2001.
16. Sekhar RV, Jahoor F, Visnegarwala F, et al. Sysregulation of lipid turnover is a key defect in the HIV lipodystrophy syndrome. Antivir Ther. 2000; 5(suppl 5):38.
17. Garrabou G, López S, Morén C, et al. Mitochondrial damage in adipose tissue of untreated HIV-infected patients. AIDS. 2011;25:165-170.
18. Milazzo L, Menzaghi B, Caramma I, et al. Effect of antioxidants on mitochondrial function in HIV-1-related lipoatrophy: a pilot study. AIDS Res Hum Retroviruses. 2010;26:1207-1214.
19. Noguera A, Morén C, Rovira N, et al. Evolution of mitochondrial DNA content after planned treatment interruption of HIV-infected pediatric patients. AIDS Res Hum Retroviruses. 2010;26:1-4.
20. Morén C, Noguera-Julian A, Rovira N, et al. Mitochondrial assessment in asymptomatic HIV-infected pediatric patients on Highly Active Antiretroviral Therapy. Antivir Ther. In press.
21. Asensi V, Rego C, Montes AH, et al. IL-1beta (-3954C/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome. Genet Med. 2008;10:215-223. (Pubitemid 351416819)